Stay updated on Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma Clinical Trial page.

Latest updates to the Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has removed extensive details about a randomized phase II study of pembrolizumab in esophageal adenocarcinoma, including the study's aims, inclusion and exclusion criteria, and the principal investigator's name. It has added a new version number and the name of a collaborator.SummaryDifference37%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 19, 2025.SummaryDifference0.2%
- Check38 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check45 days agoChange DetectedThe page has updated its date references, removing older dates from 2024 and adding new dates in March 2025. This indicates a shift in the timeline of the content presented.SummaryDifference0.8%
- Check74 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma Clinical Trial page.